The EPS projection of PTC Therapeutics, Inc. (NASDAQ:PTCT) for quarter ended 2016-09-30 is $-1.12. A week before, the EPS forecast was $-1.12 against target of $-1.12, a month earlier. This estimate stood at $-1.12 60 days earlier versus forecast of $-1.12 90 days earlier, confirming a deviation of 0%.
PTC Therapeutics, Inc. (NASDAQ:PTCT) reported that 18 days ago, the positive EPS revisions were 1 and negative revisions at 1.
In last week, the per-share earnings was lowered 0 times and 0 times positively. In last 120, 60, 30 and 90 days the positive revisions were 0, 2, 0 and 2, respectively.
The downgrade of EPS estimates for PTC Therapeutics, Inc. (NASDAQ:PTCT) in the preceding 120, 60, 30 and 90 days were 1, 1, 0 and 1, in that order.
As per the latest update, for the quarter closed 1, the EPS estimate of PTC Therapeutics, Inc. (NASDAQ:PTCT) was $-1.12. This projection was computed after accounting 6 calls. As reported on 2016-05-05 the EPS was $-1.16. The change was $0.05, demonstrating a percentage deviation of 4.13%. The projections confirmed a standard deviation of 0.24.
Quarterly Sales Estimates
For the fiscal 2016, the yearly sales target for PTC Therapeutics, Inc. (NASDAQ:PTCT) stands at $22.63 and the median estimate at $21.901. Almost 3 analysts announced their estimates.
The highest estimate is $25.89 while the lowest target is $20.1 showing standard deviation of 2.963%.
As many as 3 analysts released sales estimates reised in upside while 3 reduced sales estimates, demonstrating a deviation of 0%.
In last month, 3 revised sales number projection on upside while 3 lowered the sales target, demonstrating a deviation of 0%.
A quarter ago, 3 hiked sales estimations and 3 reduced sales forecast. PTC Therapeutics, Inc. (NASDAQ:PTCT) stated that the change in forecast was -4.215%.
1 Chart Pattern Every Investor Should Know
This little-known pattern preceded moves of 578% in ARWR, 562% in LCI, 513% in ICPT, 439% in EGRX, 408% in ADDUS and more...